Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Major players are active in this area…<br />
…Yet opportunities remain for novel therapies<br />
Phase I/II<br />
Denosumab<br />
Amgen<br />
Ocrelizumab<br />
<strong>Roche</strong><br />
Orals<br />
e.g. p38<br />
HuMax 20<br />
GenMab<br />
Belimumab<br />
HGS/CAT/GSK<br />
Tru015<br />
Trubion/Wyeth<br />
Phase III<br />
Actemra<br />
<strong>Roche</strong><br />
Cimzia<br />
Celltech/UCB<br />
Golimumab<br />
J&J<br />
Launched<br />
Enbrel<br />
Amgen<br />
Remicade<br />
J&J<br />
Humira<br />
Abbott<br />
MabThera<br />
<strong>Roche</strong><br />
Orencia<br />
BMS<br />
1998 1999 2000 2001 2002 2003 2004 2005<br />
2006<br />
2008 and later<br />
Anti-TNF Other MoA Costimulation modulator B-Cell Targeted Therapy <strong>Roche</strong><br />
60